Clin2
NCT06754423Likely a fitRecruiting

Registry for men with CAH (21-hydroxylase deficiency)

Congenital Adrenal Hyperplasia

Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial is creating a registry to track adult males with congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency. It helps doctors learn more about the condition and how it changes over time.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You identify as male.
  • You are at least 18 years old.
  • You have been diagnosed with congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
  • You have already had a genetic test (CYP21A2 gene analysis) that found the specific mutation causing your CAH.
  • You are willing to sign a consent form agreeing to join the registry.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07159841Recruiting· Phase 2/Phase 3
Study of a new drug for children with classic CAH

This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.

San Francisco, California
NCT05669950Recruiting· Phase 1/Phase 2
Study drug Lu AG13909 for congenital adrenal hyperplasia

This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.

Ann Arbor, Michigan
NCT07611786Not yet recruiting
Healthcare Transition Support for Young Adults With Congenital Adrenal Hyperplasia

This study helps young people with congenital adrenal hyperplasia (a condition affecting hormone production) move smoothly from pediatric to adult care. Researchers will develop and test a transition program with patients, caregivers, and healthcare providers to make this shift easier and safer.

Birmingham, Alabama
NCT07144163Recruiting· Phase 3
Atumelnant for adults with classic CAH

This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.

Los Angeles, California
NCT07536269Not yet recruiting· Phase 2
Safety study of crinecerfont for very young children with CAH

This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.

NCT07718230Not yet recruiting
Steroid levels check in congenital adrenal hyperplasia

This study checks hormone levels in saliva and blood using a precise test to better understand how the body balances steroids in people with congenital adrenal hyperplasia, a condition that affects hormone production.

Paris

Hear when a new Congenital Adrenal Hyperplasia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.